Find a Local Lawyer

Close This Box!

Seton Hall Law School?s Center for Health and Pharmaceutical Law and the Seton Hall Law Review will be hosting a symposium on October 23-24, 2008, to examine the legal, ethical, and public policy issues related to developing a pharmaceutical response to an influenza pandemic. Panels will explore issues related to the development and approval of vaccines and antiviral drugs, both before and during a pandemic; the allocation of vaccines and antiviral drugs in situations of scarcity; pricing issues; and liability and compensation for drug-related injuries. There will be a special emphasis on issues related to international equity.

The symposium will be held at Seton Hall Law School?s campus in downtown Newark, New Jersey, which is a short walk from Newark Penn Station and a short taxi ride from Newark International Airport. (It is also about a 25 minute train ride from Manhattan via NJ Transit, Amtrak, or PATH.) The symposium will be widely publicized to academics, government officials, pharmaceutical industry representatives, and the public, and admission will be free. Papers from the symposium will be published in a special issue of the Seton Hall Law Review, which will be disseminated free of charge to a broad group of stakeholders, including key government and industry representatives.

Persons interested in participating as a panelist at the symposium should submit a CV and a 200-word abstract of their presentation to Julie Sauer, Symposium Editor, by April 15, 2008. Julie Sauer may be reached at (201) 739-7310 / sauerjul@shu.edu. Prospective panelists should indicate whether they would be interested in submitting a paper based on their presentation for publication in the Seton Hall Law Review. Contributions are welcome from scholars and practitioners in all disciplines.

Confirmed speakers for the event include Thomas Pogge, Professor of Political Science and Philosophy at Columbia University, Kevin Outterson, Professor of Law at Boston University School of Law, and Adel Mahmoud M.D., former president of Merck Vaccines, now at Princeton's Woodrow Wilson School.